Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's

Research paper by Rania Soudy, Aarti Patel, Wen Fu, Kamaljit Kaur, David MacTavish, David Westaway, Rachel Davey, Jeffrey Zajac, Jack Jhamandas

Indexed on: 10 Dec '16Published on: 10 Dec '16Published in: Alzheimer's & Dementia: Translational Research & Clinical Interventions


Amylin receptor serves as a portal for the expression of deleterious effects of amyloid β-protein (Aβ), a key pathologic hallmark of Alzheimer's disease. Previously, we showed that AC253, an amylin receptor antagonist, is neuroprotective against Aβ toxicity in vitro and abrogates Aβ-induced impairment of hippocampal long-term potentiation.

Figure 10.1016/j.trci.2016.11.005.0.jpg
Figure 10.1016/j.trci.2016.11.005.1.jpg
Figure 10.1016/j.trci.2016.11.005.2.jpg
Figure 10.1016/j.trci.2016.11.005.3.jpg
Figure 10.1016/j.trci.2016.11.005.4.jpg
Figure 10.1016/j.trci.2016.11.005.5.jpg